[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"meibomian-gland-dysfunction-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:meibomian-gland-dysfunction-disorder":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,75,105,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100640755","tearcare-in-young-adults-100640755",false,"NCT07579156","TearCare in Young Adults","Inclusion Criteria:\n\n1. Age ≥18 years but \\\u003C30 years of age\n2. Non-invasive Keratograph break-up time (NIKBUT) \\\u003C10 seconds in at least one eye\n3. Meibomian gland secretion score (MGSS) ≤23 for 15 glands in at least one eyelid\n4. OSDI ≥23\n\nExclusion Criteria:\n\n1. Contact lens wear within two weeks of study enrollment or planned during study period\n2. Habitual visual acuity worse than 0.30 logMAR (Snellen equivalent of 20\u002F40) in either eye\n3. Previous or current diagnosis of any autoimmune condition\n4. Use of any of the following medications within 60 days of enrollment:\n\n   1. Topical ophthalmic cyclosporine (including but not limited to Restasis®, Cequa®, Vevye®, generic, or compounded versions)\n   2. Xiidra®\n   3. Miebo®\n   4. Tyrvaya®\n   5. Tryptyr®\n5. Use of topical ocular steroids within 30 days of enrollment\n6. Use of any other topical ophthalmic drop, excluding artificial tears, within 7 days\n7. Use of oral tetracyclines or oral azithromycin within 30 days\n8. Present or past use of oral isotretinoin\n9. Any of the following procedural treatments for MGD in the past:\n\n   1. LipiFlow®\n   2. TearCare®\n   3. iLux®\n   4. Intense pulsed light (IPL)\n10. Previous intraocular surgery within 6 months of enrollment\n11. Previous refractive surgery within 2 years of enrollment\n12. Current or planned pregnancy during the study period\n13. Current or planned lactation during the study period\n14. Females of childbearing potential who are not using effective contraception\n15. Dose modification of oral antihistamines or antidepressants within 30 days of enrollment\n16. Current enrollment or enrollment within 60 days in any other study of an investigational drug or device\n17. Clinical opinion of the study doctor based on clinical examination and\u002For participant compliance with protocol requirements","ALL","18 Years","29 Years",{"count":19,"type":20},45,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study is a non-randomized, open-label, interventional trial of TearCare® eyelid warming and manual meibomian gland expression in young adults with clinically significant meibomian gland dysfunction (MGD). Intervention is with TearCare® performed at Visit 1. A single follow-up examination occurs at Day 28.",[26],"Meibomian Gland Dysfunction (Disorder)",[28,29,30,31],"Meibomian Gland Dysfunction","TearCare","Ocular Surface Inflammation","Dry Eye Disease","NOT_YET_RECRUITING","2026-05-04",{"date":35,"type":36},"2026-05-11","ACTUAL",{"date":38,"type":20},"2026-08-01",{"date":40,"type":20},"2027-12-01",{"name":42,"class":43},"University of Alabama at Birmingham","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100626015","blink-reminders-and-meibomian-gland-loss-in-digital-screen-users-100626015","NCT07430137","Blink Reminders and Meibomian Gland Loss in Digital Screen Users","Effect of a Blink Reminder Program on the Progression of Meibomian Gland Loss in Intensive Digital Screen Users: a Randomized Controlled Trial With Infrared Meibography","Inclusion Criteria:\n\n* Participants aged 18 to 40 years.\n* Intensive digital screen users, defined as an average screen time of ≥4 hours per day for at least 3 days per week.\n* Ocular Surface Disease Index (OSDI) score ≥13 (indicating mild to severe symptoms).\n* Non-invasive tear break-up time (NIBUT) ≤10 seconds measured by infrared meibography.\n* Presence of visible Meibomian glands on baseline meibography, allowing for quantitative analysis.\n* Technical ability to install and operate the BlinkEasy software on their primary digital device.\n\nExclusion Criteria:\n\n* Active ocular disease, including infections, corneal ulcers, or acute conjunctivitis.\n* History of ocular surgery (e.g., refractive surgery, cataract extraction) or significant ocular injury.\n* Use of topical ophthalmic medications affecting the ocular surface (e.g., steroids, glaucoma medications, or cyclosporine) within the last 3 months.\n* Active use of contact lenses that cannot be suspended for the duration of the 12-week study period.\n* Systemic conditions known to affect the ocular surface (e.g., Sjögren's syndrome, Rheumatoid Arthritis).\n* Diagnosis of Diabetes Mellitus (Type 1 or Type 2).","40 Years",{"count":54,"type":20},28,[23],"This randomized clinical trial aims to evaluate if a blink reminder program ('BlinkEasy') reduces the progression of Meibomian gland loss in intensive digital screen users over three months , using infrared meibography as the primary structural measure. Additionally, the study will analyze changes in dry eye symptoms using the 12-item Ocular Surface Disease Index (OSDI) questionnaire and non-invasive tear break-up time (NIBUT).",[58,26],"Dry Eye Syndromes",[60,61,62,63,64,65],"Dry eye","Blinking","Meibography","Digital Displays","Meibomian Gland Atrophy","BlinkEasy","2026-02-25",{"date":68,"type":36},"2026-02-27",{"date":70,"type":20},"2026-02-19",{"date":72,"type":20},"2026-08",{"name":74,"class":43},"Asociación para Evitar la Ceguera en México",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":15,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":44},"100618291","comparing-tear-proteomics-profile-in-dry-eye-disease-pre-and-post-treatment-with-low-level-light-therapy-100618291","NCT07329712","Comparing Tear Proteomics Profile in Dry Eye Disease pre-and Post-treatment With Low Level Light Therapy","Inclusion Criteria:\n\n1. Must be eligible for, and have consented for low level light therapy\n2. Must not have presented to the clinic for an acute eye problem such as visual loss or painful eye\n3. Ability to give informed consent.\n4. Age more or equals to 21 years old.\n\nExclusion Criteria:\n\n1. Patients who are unable to or decline to give consent.\n2. Age less than 21 years old.\n3. Patients who presented to the clinic for an acute eye problem such as visual loss or painful eye.\n4. Patients not suitable for low level lighttherapy:\n\n   * Pregnant\n   * Fitted with pacemakers, metal, electrical, acoustic prosthetics\n   * Epilepsy, cardiac rhythm or frequency disorders\n   * Fever, thrombophlebitis or acute phlebitis of the legs, large-sized varicose veins, or venous surgery within 2 months\n   * Uncontrolled hypertension or severe diabetes\n   * Open wounds on eyelid or skin\n   * Evolving cancer or hepatitis\n   * Blood anticoagulant or coagulation defect","21 Years",{"count":83,"type":20},30,"OBSERVATIONAL","The purpose of this research study is to understand the mechanism of action of low level light therapy and also potentially yield markers associated with good treatment response. Low-level light therapy is light-based treatment delivered through advance eye-light device. This therapy uses light energy to provide energy to the meibomian gland cells to slow down age-ing, improve tear stability and reduce inflammation.",[87,26],"Dry Eye",[87,89,90,91,92,93],"low level light therapy","Eyelight","Tears proteomics","tear cytokine","MGD","RECRUITING","2026-01-06",{"date":97,"type":36},"2026-01-09",{"date":99,"type":36},"2025-11-05",{"date":101,"type":20},"2027-12-31",{"name":103,"class":104},"Singapore National Eye Centre","OTHER_GOV",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":113,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":126,"locationsCount":44},"100606282","low-level-light-therapy--skin-pigmentation-100606282","NCT07173530","Low Level Light Therapy & Skin Pigmentation","Inclusion Criteria:\n\n* Ability to read and understand the study informed consent in English\n* Age 18 years or older at enrollment\n* Individuals with MGD based on one or more of the following clinical signs\u002Fsymptoms, e.g., meibum quality score of 1-3 (Bron et al.), meibography score of 1, 2, or 3 on the Pult Meiboscale, non-invasive 1st tear break up time of 10 seconds or less, or an Ocular Surface Disease Index (OSDI) score greater than 12 points.\n\nExclusion Criteria:\n\n* Active anterior segment pathology (e.g., bacterial conjunctivitis, microbial keratitis)\n* History of systemic disease associated with aqueous-deficient dry eye disease (e.g., Sjogren's syndrome)\n* History of corneal surgery, refractive surgery, or eyelid surgery within 6 months\n* History of corneal ectasia (e.g. keratoconus, Pellucid marginal degeneration)\n* History of ocular trauma within 6 months\n* History of LipiFlow, iLux, Meiboflow, IPL or LLLT within the last 12 months\n* Habitual use of photosensitizing medications within the last 30 days\n* Pregnant and\u002For lactating females, by self-report\n* Pigmented lesions, tattoos, or skin cancer in the periocular region\n* Unwilling to have eyes photographed or video recorded",{"count":112,"type":20},40,[23],"The goal of this clinical trial is to determine if there is a difference in eyelid temperature after low-level light therapy (LLLT) in individuals with different amounts of skin pigmentation and dry eye\u002Fmeibomian gland disease. Participants will have 3 fifteen minute in office LLLT therapy sessions over a period of approximately 7 to 14 days.",[87,26],[87,117,118,119],"Meibomian Gland","LLLT","Low-level light therapy","2025-09-08",{"date":122,"type":36},"2025-09-15",{"date":124,"type":36},"2025-06-11",{"date":72,"type":20},{"name":127,"class":43},"University of Houston",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":21,"phases":137,"briefSummary":139,"conditions":140,"keywords":147,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":44},"100594024","phase-2-autologous-serum-obtained-by-a-closed-circuit-collection-device-100594024","NCT07014059","Autologous Serum Obtained by a Closed-Circuit Collection Device","\"In Vivo Evaluation of Topical Ocular Use of Autologous Serum Obtained by a Closed-Circuit Collection Device.\"","Inclusion Criteria:\n\n* ≥ 18 years\n* Dry eye and\u002For chronic epithelial defects of the ocular surface with indication for autologous serum according to the evaluation of ophthalmologists specialized in Cornea and Ocular Surface;\n* Peripheral venous access or PICC that allows the collection of whole blood.\n\nExclusion Criteria:\n\n* Active ocular infection;\n* Hemoglobin \\\u003C 11 g\u002FdL;\n* Angina, MI, or stroke in the last 30 days;\n* Significant pulmonary or cardiac disease that contraindicates autologous serum collection in the investigator's opinion;\n* Active ocular or systemic infection at the time of collection;\n* Inability to attend follow-up visits at 6 and 12 weeks;\n* Active hematological malignancy (except measurable residual disease) or solid malignancy (except non-melanoma skin cancer);\n* Positive for HIV, HCV, HBV, HTLV, Chagas disease, or syphilis;\n* Life expectancy \\\u003C 6 months;\n* Not pregnant (as reported by the participant).",{"count":136,"type":20},16,[138],"PHASE2","Autologous serum eye drops (ASED) are an established therapy for ocular surface diseases; however, their preparation can be costly and may not be available due to the need for germ-free conditions. This pilot trial assesses the feasibility of collecting ASED in a closed-circuit system for patients with chronic ocular surface diseases.",[141,26,142,143,144,145,146],"GVHD","Stevens-Johnson Syndrome","Limbal Keratoconjunctivitis","Recurrent Erosions of Persistent Epithelial Defects","Neurotrophic Ulcer","Sjogren Syndrome With Keratoconjunctivitis",[148,149,150,26,142,143,145,144,151,152],"soro autologo","gvhd","Sjogren's Syndrome (SS)","Study Protocol - Autologous Serum","Autologous Serum","2025-06-02",{"date":155,"type":36},"2025-06-10",{"date":157,"type":20},"2025-06-20",{"date":159,"type":20},"2027-06-20",{"name":161,"class":43},"GIANCARLO FATOBENE"]